Attitudes Toward HIV Protease Inhibitors and Medication Adherence in an Inner City HIV Population

AIDS Patient Care and STDs

Volumn 17, Issue 11, 2003, Pages 575-580

  Demmer, Craig ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ILLICIT DRUG; PROTEINASE INHIBITOR;

ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PATIENT COMPLIANCE; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; AFRICAN AMERICANS; ATTITUDE TO HEALTH; FEMALE; HISPANIC AMERICANS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; NEW YORK CITY; PATIENT COMPLIANCE; PILOT PROJECTS; RURAL HEALTH;

EID: 0345686520     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/108729103322555962     Document Type: Article

References (30)

1. Altice FL, Friedland GH. The era of adherence to HIV therapy. Ann Intern Med 1998;129:503-505.
2. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
3. Chesney MA, Morin M, Sherr L. Adherence to HIV combination therapy. Soc Sci Med 2000;50:1599-1605.
4. Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. JAMA 1999;282:1135-1141.
5. Bangsburg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000;14:357-366.
6. Halkitis PN, Parsons JT, Wolitski RJ, Remien RH. Characteristics of HIV antiretroviral treatments, access and adherence in an ethnically diverse sample of men who have sex with men. AIDS Care 2003;15: 89-102.
7. Erlen JA, Sereika SM, Cook RL, Hunt SC. Adherence to antiretroviral therapy among women with HIV infection. J Obstet Gynecol Neonatal Nurs 2002;31: 470-477.
8. Duran S, Solas C, Spire B, et al. "Do HIV-infected injecting drug users over-report adherence to highly active antiretroviral therapy?" A comparison between patients' self-reports and serum protease inhibitor concentration in the French Manif 2000 cohort study. AIDS 2001;15:1075-1077.
9. Belzer ME, Fuchs DN, Luftman DO, Tucker DJ. Antiretroviral adherence issues among HIV-positive adolescents and young adults. Adolesc Heal Brief 1999;25:316-319.
10. Roca B, Gomez CJ, Arnedo A. Adherence, side effects and efficacy of stavudine plus lamivudine plus nelfinavir in treatment-experienced HIV-infected patients. J Infect 2000;41:50-54.
11. Van Dyke RB, Lee S, Johnson ZGM, et al. Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics 2002;109:e61.
12. Watson DC, Farley JJ. Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J 1999;18:682-689.
13. Murphy DA, Wilson CM, Durako SJ, Muenz M, Belzer M. Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. AIDS Care 2000;13:27-40.
14. Turner BJ, Newschaffer CJ, Zhang D, Cosler L, Hauck WW. Antiretroviral use and pharmacy-based measurement of adherence in postpartum HIV-infected women. Med Care 2000;38:911-925.
15. Maher K, Klimas N, Fletcher V, et al. Disease progression, adherence, and response to protease inhibitor therapy for HIV infection in an urban Veteran Affairs Medical Center. J Acquir Immune Defic Syndr 1999;22:358-363.
16. Escaffre N, Morin M, Bouhnik AD, et al. Injecting drug users' adherence to HIV antiretroviral treatments: physicians' beliefs. AIDS Care 2000;12: 723-730.
17. Weidle PJ, Ganea C, Irwin KL, et al. Adherence to antiretroviral medications in an Inner-City Population. J Acquir Immune Defic Syndr 1999;22:498-502.
18. Chesney MA, Ickovics J, Hecht FM, et al. Adherence: a necessity for successful HIV combination therapy. AIDS 1999;13:S271-S278.
19. Demmer C. Nonadherence to HIV treatment: implications for health educators. Amer J Health Educ 2001;32:16-23.
20. Eldred LJ, Wu AW, Chaisson RE, Moore RD. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:117-125.
21. Geletko SM, Ballard CR, Matthews WC. Health beliefs and discontinuation of zidovudine therapy. Am J Health-Syst Pharm 1995;52:505-507.
22. Nannis SA, Temoshok LR, Smith M, Jenkins RA. Perceptions of AZT: Implications for adherence to medical regimens. J Appl Biobehav Res 1993;1:39-54.
23. Muma RD, Ross MW, Parcel GS, Pollard RB. Zidovudine adherence among individuals with HIV infection. AIDS Care 1995;7:439-447.
24. Heath KV, Hogg RS, Chan KJ, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population based HIV/AIDS treatment database. AIDS 2001;15:231-239.
25. Barreiro P, Garcia-Benayas T, Soriano V, Gallant J. Simplification of antiretroviral treatment-How to sustain success, reduce toxicity and ensure adherence avoiding PI use. AIDS Rev 2002;4:233-241.
26. Siegel K, Karus D, Schrimshaw EW. Racial differences in attitudes toward protease inhibitors among older HIV-infected men. AIDS Care 2000;12:423-434.
27. Holzemer WL, Corless IB, Nokes KM, et al. Predictors of self-reported adherence in persons living with HIV disease. AIDS Patient Care STDs 1999;13: 185-197.
28. Williams AB. Adherence to highly active antiretroviral therapy. Nurs Clin North Am 1999;34:113-129.
29. Hugen PW, Langebeek N, Burger DM, et al. Assessment of adherence to HIV protease inhibitors: Comparison and combination of various methods, including MEMS, patient and nurse report, and therapeutic drug monitoring. J Acquir Immune Defic Syndr 2002;30:324-334.
30. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2002;134:968-977.